7. Roivant Sciences Ltd. (NASDAQ:ROIV)
Roivant Sciences Ltd. (NASDAQ: ROIV) rose 14.89 percent on Wednesday to close at $32.41 per share, as investors reacted positively to the company’s swing to profitability in the fourth quarter of fiscal year 2026 and positioned ahead of the expected commercial launch of its autoimmune disease treatment. In a stock market where biotech stocks often move on clinical data, regulatory updates, FDA decisions, pipeline milestones, and commercialization timelines, Roivant gave investors several reasons to pay attention.
The company reported attributable net income of $302.99 million for the quarter, a major turnaround from an attributable net loss of $206.47 million in the same period last year. That improvement was helped by operating income of $415 million, compared with an operating loss of $284.96 million a year earlier. For investors, the swing to profitability was important because many biotechnology companies continue to burn cash while waiting for clinical or regulatory breakthroughs. Roivant’s bottom-line improvement helped separate it from more speculative biotech names that still have limited revenue and no near-term commercial catalyst.
There was one important caveat, however. Revenue fell 66.7 percent to $2.52 million from $7.57 million in the same quarter last year. That decline shows that Roivant’s story is still not simply about current sales. Instead, the market appears to be focusing more heavily on the company’s future product opportunity, especially its planned commercial launch of brepocitinib by the end of September. The oral treatment is being developed for severe and rare autoimmune conditions, a category that can attract investor interest because successful therapies may serve high-need patient populations and command meaningful market value.
Roivant said the U.S. Food and Drug Administration has officially accepted its new drug application for brepocitinib, with a target action date assigned in the third quarter of the year. That FDA timeline is now one of the most important catalysts for the company. Biotech investors often watch these regulatory dates closely because an approval can change the commercial profile of a company almost overnight, while a delay or rejection can quickly reverse market enthusiasm.
For readers tracking the best biotech stocks, FDA approval stocks, autoimmune disease treatment stocks, pharmaceutical market movers, and healthcare stocks rising today, Roivant’s rally was one of the most important moves of the session. The company’s profitability swing gave the stock immediate support, but the bigger investor question is whether brepocitinib can become a meaningful commercial product. That is the story Wall Street appears to be pricing more aggressively after Wednesday’s gain.
Click next to see the following stock...
